Clinical trials
Carcinosarcoma clinical trials
Below are recruiting carcinosarcoma clinical trials, each written for real people, not researchers. We’re tracking 20 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05920798RecruitingPhase 1/Phase 2
Vaccine treatment plus pembrolizumab for recurrent ovarian cancer
This Phase 1/2 trial tests a new cancer vaccine therapy combined with pembrolizumab (an immunotherapy) to treat advanced, recurrent ovarian, fallopian tube, or primary peritoneal cancer. It may help your immune system recognize and attack the cancer, especially if your tumor has a specific target called FRα.
Scottsdale, ArizonaAges 18 years+ - NCT03651206RecruitingPhase 2/Phase 3
Study of niraparib and anti–PD-1 for recurrent uterine cancer
This trial studies whether blocking PD-1 (an immune “brake”) along with niraparib (a DNA-repair blocker) can shrink or control recurrent/progressive uterine carcinosarcoma after prior chemotherapy. It’s for people whose cancer has grown again and who meet specific health and lab requirements.
AngersAges 18 years+ - NCT06639074RecruitingPhase 2
Folate receptor dendritic cell vaccine for ovarian cancer
This trial tests a personalized vaccine made from your own immune cells, designed to target a protein called folate receptor alpha found on many ovarian cancer cells. It is for people who have finished initial chemotherapy and have no signs of cancer remaining, to try to prevent it from coming back.
Scottsdale, ArizonaAges 18 years+ - NCT04919629RecruitingPhase 2
Tested treatments for recurrent ovarian cancer with fluid buildup
This Phase 2 study tests whether adding two medicines—APL-2 plus pembrolizumab or pembrolizumab plus bevacizumab—works better than bevacizumab alone for recurrent ovarian, fallopian tube, or primary peritoneal cancer. It also focuses on people who have symptoms from cancer-related fluid (ascites or pleural effusion).
Buffalo, New YorkAges 18 years+ - NCT06483048RecruitingPhase 1
MUC1-targeted T cells for relapsed ovarian cancer
This trial tests a new treatment using your own immune cells, modified to target a protein called MUC1 on ovarian cancer cells. It is for people with ovarian cancer that has come back or is resistant to standard treatments.
Scottsdale, ArizonaAges 18 years+ - NCT05269381RecruitingPhase 1/Phase 2
Personalized cancer vaccine with pembrolizumab for advanced solid tumors
This trial tests a personalized vaccine made from your tumor's unique markers, combined with the drug pembrolizumab, to help your immune system fight cancer. It is for people with advanced solid tumors who have already tried standard treatments.
Jacksonville, FloridaAges 16 years+ - NCT07741968Recruiting
Online program to ease fear of cancer returning
This study tests an online program designed to help women with advanced or certain types of breast or gynecologic cancer manage their fear of the disease progressing or returning. The program aims to reduce anxiety and improve quality of life.
Arcadia, CaliforniaAges 18 years+ - NCT06580314RecruitingPhase 3
Olaparib with or without bevacizumab for ovarian cancer
This trial tests whether taking the drug olaparib for one or two years, alone or with another drug called bevacizumab, can help keep ovarian cancer from coming back after initial chemotherapy and surgery. It is for people with certain genetic markers in their tumor.
Birmingham, AlabamaAges 18 years+ - NCT05902988RecruitingPhase 1/Phase 2
Study of VLS-1488 for advanced cancers
This early-phase study tests VLS-1488, a new cancer medicine, in people with advanced cancers that have limited treatment options. It may help by finding a safe dose and whether it can shrink or control tumors.
Los Angeles, CaliforniaAges 18 years+ - NCT05256225RecruitingPhase 3
Adding Herceptin medicines to chemo for HER2-positive endometrial cancer
This Phase 3 trial tests whether adding Herceptin Hylecta or Phesgo to standard chemotherapy works better than chemotherapy alone for HER2-positive serous endometrial cancer or carcinosarcoma. It may help by improving how well treatment controls or shrinks the cancer.
Birmingham, AlabamaAges 18 years+ - NCT05646316RecruitingPhase 3
Sentinel lymph node mapping to reduce leg swelling after surgery
This study tests whether a special way of finding lymph nodes during hysterectomy can lower the risk of long-term leg swelling or related dysfunction in people with stage I endometrial cancer. It compares standard lymph node assessment with sentinel lymph node mapping and looks at how this affects day-to-day leg functioning.
Washington D.C., District of ColumbiaAges 18 years+ - NCT03422198RecruitingPhase 3
Short course vaginal radiation after hysterectomy
This trial tests a short course of targeted vaginal radiation (brachytherapy) after surgery for certain early endometrial cancer. It may help prevent the cancer from coming back in the vaginal area after the uterus has been removed.
Palo Alto, CaliforniaAges Any age - NCT04122872Recruiting
German sarcoma registry for adults with rare tumor types
This study is a German “registry,” meaning it collects information about people with specific bone or soft tissue tumors (including some borderline or hard-to-classify cases). It helps doctors and researchers learn more about these rare conditions to improve future care.
Tübingen, Baden-WurttembergAges 18 years+ - NCT05049538Recruiting
Liquid blood tests to predict endometrial cancer return
This trial studies whether blood “liquid biopsies” and tumor genetic testing can help predict whether endometrial cancer will come back after treatment. Results may help doctors plan follow-up and additional care based on a person’s recurrence risk.
Houston, TexasAges 18 years+ - NCT05500391RecruitingPhase 2
Testing whether remote nurse monitoring works like in-person checks
This Phase 2 study compares two ways of checking your cancer follow-up: a doctor or nurse visits in person versus remote monitoring by phone and imaging. The goal is to see whether remote monitoring can safely replace or match in-person care for certain low-risk cancers and after surgery.
AmiensAges 18 years+ - NCT05542407RecruitingPhase 1
ONC201 plus atezolizumab for endometrial cancer and obesity
This Phase 1 study tests ONC201 together with atezolizumab in people with metastatic or returning endometrial cancer, especially when obesity may be driving the cancer. It aims to find a safe dose and see whether the combination can slow the cancer’s growth.
Chapel Hill, North CarolinaAges 18 years+ - NCT05559879RecruitingPhase 1/Phase 2
Cabozantinib and dostarlimab for recurrent gynecologic carcinosarcoma
This trial tests the combination of cabozantinib and dostarlimab to treat recurrent (coming back) gynecologic carcinosarcoma, after standard chemotherapy has already been tried. It aims to shrink tumors and improve outcomes by targeting cancer pathways.
Birmingham, AlabamaAges 18 years+ - NCT06349642Recruiting
Testing a live tumor test for immune therapy response
This trial uses a special test on live tumor samples to see if it can predict how well immune checkpoint inhibitors (a type of immunotherapy) will work for different cancers. It may help doctors choose the best treatment for you.
Phoenix, ArizonaAges 18 years+ - NCT06541652Recruiting
Study of rare liver cancers in France
This study looks at people with rare types of liver cancer to learn more about the disease. If you have one of these rare liver cancers, your information could help doctors understand these cancers better.
AmiensAges 18 years+ - NCT06638931RecruitingPhase 2
Nivolumab for rare solid tumors with high PD-L1
This trial is testing a drug called Nivolumab (an immunotherapy) for people with rare solid tumors that have high levels of PD-L1. It might be an option if you have tried other treatments and they stopped working or caused too many side effects.
Fortaleza, CearáAges 18 years+
Hear when a new Carcinosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for carcinosarcoma?
- Yes. Clin2 currently lists 20 recruiting carcinosarcoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a carcinosarcoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a carcinosarcoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.